## Stefania Croci

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6521540/publications.pdf

Version: 2024-02-01

94 papers 2,309 citations

26 h-index 233125 45 g-index

98 all docs 98 docs citations 98 times ranked 3101 citing authors

#	Article	IF	Citations
1	Antitumor Activity of the Insulin-Like Growth Factor-I Receptor Kinase Inhibitor NVP-AEW541 in Musculoskeletal Tumors. Cancer Research, 2005, 65, 3868-3876.	0.4	272
2	Rehabilitation Interventions for Post-Acute COVID-19 Syndrome: A Systematic Review. International Journal of Environmental Research and Public Health, 2022, 19, 5185.	1.2	95
3	Uveitis and Other Ocular Complications Following COVID-19 Vaccination. Journal of Clinical Medicine, 2021, 10, 5960.	1.0	92
4	Immunoprevention of Mammary Carcinoma in HER-2/neu Transgenic Mice Is IFN- $\hat{I}^3$ and B Cell Dependent. Journal of Immunology, 2004, 173, 2288-2296.	0.4	88
5	Immunoprevention of HER-2/neu Transgenic Mammary Carcinoma through an Interleukin 12-Engineered Allogeneic Cell Vaccine. Cancer Research, 2004, 64, 4001-4009.	0.4	87
6	Inhibition of Connective Tissue Growth Factor (CTGF/CCN2) Expression Decreases the Survival and Myogenic Differentiation of Human Rhabdomyosarcoma Cells. Cancer Research, 2004, 64, 1730-1736.	0.4	83
7	Inhibition of human tumor growth in mice by an oncolytic herpes simplex virus designed to target solely HER-2-positive cells. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 9039-9044.	3.3	83
8	<i>In silico</i> Modeling and <i>In vivo</i> Efficacy of Cancer-Preventive Vaccinations. Cancer Research, 2010, 70, 7755-7763.	0.4	78
9	Multiorgan Metastasis of Human HER-2+ Breast Cancer in Rag2â^'/â^';ll2rgâ^'/â^' Mice and Treatment with PI3K Inhibitor. PLoS ONE, 2012, 7, e39626.	1.1	78
10	Synthesis and Characterization of <sup>68 &lt; /sup&gt;Ga-Labeled Curcumin and Curcuminoid Complexes as Potential Radiotracers for Imaging of Cancer and Alzheimer's Disease. Inorganic Chemistry, 2014, 53, 4922-4933.</sup>	1.9	71
11	Ectopic expression of CXCL13, BAFF, APRIL and LT- $\hat{l}^2$ is associated with artery tertiary lymphoid organs in giant cell arteritis. Annals of the Rheumatic Diseases, 2017, 76, 235-243.	0.5	67
12	Development of rhabdomyosarcoma in HER-2/neu transgenic p53 mutant mice. Cancer Research, 2003, 63, 2728-32.	0.4	53
13	New insights into the pathogenesis of giant cell arteritis. Autoimmunity Reviews, 2017, 16, 675-683.	2.5	51
14	Rituximab therapy for Takayasu arteritis: a seven patients experience and a review of the literature. Rheumatology, 2018, 57, 1151-1155.	0.9	50
15	Susceptibility and severity of COVID-19 in patients treated with bDMARDS and tsDMARDs: a population-based study. Annals of the Rheumatic Diseases, 2020, 79, 986.2-988.	0.5	49
16	Antimetastatic Activity of a Preventive Cancer Vaccine. Cancer Research, 2007, 67, 11037-11044.	0.4	47
17	Identification of new genes related to the myogenic differentiation arrest of human rhabdomyosarcoma cells. Gene, 2001, 274, 139-149.	1.0	46
18	Gene Expression Analysis of Immune-Mediated Arrest of Tumorigenesis in a Transgenic Mouse Model of HER-2/neu-Positive Basal-Like Mammary Carcinoma. American Journal of Pathology, 2005, 166, 1205-1216.	1.9	43

#	Article	IF	CITATIONS
19	Complex interplay between neutral and adaptive evolution shaped differential genomic background and disease susceptibility along the Italian peninsula. Scientific Reports, 2016, 6, 32513.	1.6	41
20	Aortic dilatation in patients with large vessel vasculitis: A longitudinal case control study using PET/CT. Seminars in Arthritis and Rheumatism, 2019, 48, 1074-1082.	1.6	40
21	MicroRNA markers of inflammation and remodelling in temporal arteries from patients with giant cell arteritis. Annals of the Rheumatic Diseases, 2016, 75, 1527-1533.	0.5	37
22	Preclinical Therapy of Disseminated HER-2+ Ovarian and Breast Carcinomas with a HER-2-Retargeted Oncolytic Herpesvirus. PLoS Pathogens, 2013, 9, e1003155.	2.1	36
23	Cytokine Profiling in Aqueous Humor Samples From Patients With Non-Infectious Uveitis Associated With Systemic Inflammatory Diseases. Frontiers in Immunology, 2020, 11, 358.	2,2	36
24	No detection of varicella-zoster virus in temporal arteries of patients with giant cell arteritis. Seminars in Arthritis and Rheumatism, 2017, 47, 235-240.	1.6	35
25	Relapses and long-term remission in large vessel giant cell arteritis in northern Italy: Characteristics and predictors in a long-term follow-up study. Seminars in Arthritis and Rheumatism, 2020, 50, 549-558.	1.6	29
26	Prevention of HER-2/neu transgenic mammary carcinoma by tamoxifen plus interleukin 12. International Journal of Cancer, 2003, 105, 384-389.	2.3	28
27	Vaccines against human HER2 prevent mammary carcinoma in mice transgenic for human HER2. Breast Cancer Research, 2014, 16, R10.	2,2	27
28	High metastatic efficiency of human sarcoma cells in Rag $2\hat{l}^3$ c double knockout mice provides a powerful test system for antimetastatic targeted therapy. European Journal of Cancer, 2010, 46, 659-668.	1.3	26
29	Human Dental Pulp Stem Cells Modulate Cytokine Production in vitro by Peripheral Blood Mononuclear Cells From Coronavirus Disease 2019 Patients. Frontiers in Cell and Developmental Biology, 2020, 8, 609204.	1.8	22
30	Significance of inflammation restricted to adventitial/periadventitial tissue on temporal artery biopsy. Seminars in Arthritis and Rheumatism, 2020, 50, 1064-1072.	1.6	22
31	Unmet Needs in the Pathogenesis and Treatment of Vasculitides. Clinical Reviews in Allergy and Immunology, 2018, 54, 244-260.	2.9	21
32	Role of PD-L1 in licensing immunoregulatory function of dental pulp mesenchymal stem cells. Stem Cell Research and Therapy, 2021, 12, 598.	2.4	21
33	Opposing control of rhabdomyosarcoma growth and differentiation by myogenin and interleukin 4. Molecular Cancer Therapeutics, 2009, 8, 754-761.	1.9	20
34	Increased expression of interleukin-22 in patients with giant cell arteritis. Rheumatology, 2018, 57, 64-72.	0.9	20
35	What Do We Have to Know about PD-L1 Expression in Prostate Cancer? A Systematic Literature Review. Part 1: Focus on Immunohistochemical Results with Discussion of Pre-Analytical and Interpretation Variables. Cells, 2021, 10, 3166.	1.8	20
36	Immunological Prevention of a Multigene Cancer Syndrome. Cancer Research, 2004, 64, 8428-8434.	0.4	19

3

#	Article	IF	CITATIONS
37	Follow-Up CT Patterns of Residual Lung Abnormalities in Severe COVID-19 Pneumonia Survivors: A Multicenter Retrospective Study. Tomography, 2022, 8, 1184-1195.	0.8	19
38	Association Between Specimen Length and Number of Sections and Diagnostic Yield of Temporal Artery Biopsy for Giant Cell Arteritis. Arthritis Care and Research, 2021, 73, 402-408.	1.5	18
39	Apc10.1: AnApcMin/+ intestinal cell line with retention of heterozygosity. International Journal of Cancer, 2004, 109, 200-206.	2.3	17
40	Uptake of Ga-curcumin derivatives in different cancer cell lines: Toward the development of new potential 68 Ga-labelled curcuminoids-based radiotracers for tumour imaging. Journal of Inorganic Biochemistry, 2017, 173, 113-119.	1.5	17
41	What Do We Have to Know about PD-L1 Expression in Prostate Cancer? A Systematic Literature Review. Part 3: PD-L1, Intracellular Signaling Pathways and Tumor Microenvironment. International Journal of Molecular Sciences, 2021, 22, 12330.	1.8	16
42	Toward the Definition of Immunosuppressive Regimens With Antitumor Activity. Transplantation Proceedings, 2005, 37, 2144-2147.	0.3	15
43	Affinity of nat/68Ga-Labelled Curcumin and Curcuminoid Complexes for $\hat{l}^2$ -Amyloid Plaques: Towards the Development of New Metal-Curcumin Based Radiotracers. International Journal of Molecular Sciences, 2016, 17, 1480.	1.8	15
44	Higher expression of miR-133b is associated with better efficacy of erlotinib as the second or third line in non-small cell lung cancer patients. PLoS ONE, 2018, 13, e0196350.	1.1	15
45	Higher Frequencies of Lymphocytes Expressing the Natural Killer Group 2D Receptor in Patients With Behçet Disease. Frontiers in Immunology, 2018, 9, 2157.	2.2	13
46	64Cu and fluorescein labeled anti-miRNA peptide nucleic acids for the detection of miRNA expression in living cells. Scientific Reports, 2019, 9, 3376.	1.6	13
47	What Do We Have to Know about PD-L1 Expression in Prostate Cancer? A Systematic Literature Review (Part 6): Correlation of PD-L1 Expression with the Status of Mismatch Repair System, BRCA, PTEN, and Other Genes. Biomedicines, 2022, 10, 236.	1.4	13
48	Tumor suppressor genes promote rhabdomyosarcoma progression in p53 heterozygous, HER-2/neu transgenic mice. Oncotarget, 2014, 5, 108-119.	0.8	12
49	A Multi-DNA Preventive Vaccine for p53/Neu-Driven Cancer Syndrome. Human Gene Therapy, 2009, 20, 453-464.	1.4	11
50	Interleukin-15 is required for immunosurveillance and immunoprevention of HER2/neu-driven mammary carcinogenesis. Breast Cancer Research, 2015, 17, 70.	2.2	11
51	Proteomic and PROTEOMEX profiling of mammary cancer progression in a HERâ€2/neu oncogeneâ€driven animal model system. Proteomics, 2010, 10, 3835-3853.	1.3	10
52	Susceptibility to COVIDâ€19 in Patients Treated With Antimalarials: A Populationâ€Based Study in Emiliaâ€Romagna, Northern Italy. Arthritis and Rheumatology, 2021, 73, 48-52.	2.9	10
53	What Do We Have to Know about PD-L1 Expression in Prostate Cancer? A Systematic Literature Review. Part 4: Experimental Treatments in Pre-Clinical Studies (Cell Lines and Mouse Models). International Journal of Molecular Sciences, 2021, 22, 12297.	1.8	10
54	Clinicopathological Bird's-Eye View of Left Atrial Myocardial Fibrosis in 121 Patients With Persistent Atrial Fibrillation. Circulation: Arrhythmia and Electrophysiology, 2020, 13, e007588.	2.1	9

#	Article	IF	CITATIONS
55	What Do We Have to Know about PD-L1 Expression in Prostate Cancer? A Systematic Literature Review. Part 2: Clinic–Pathologic Correlations. Cells, 2021, 10, 3165.	1.8	9
56	Mortality Prediction of COVID-19 Patients Using Radiomic and Neural Network Features Extracted from a Wide Chest X-ray Sample Size: A Robust Approach for Different Medical Imbalanced Scenarios. Applied Sciences (Switzerland), 2022, 12, 3903.	1.3	9
57	Expression of connective tissue growth factor (CTGF/CCN2) in a mouse model of rhabdomyosarcomagenesis. Pathology and Oncology Research, 2007, 13, 336-339.	0.9	8
58	Human responses against HER-2-positive cancer cells in human immune system-engrafted mice. British Journal of Cancer, 2012, 107, 1302-1309.	2.9	8
59	Preliminary Study of a 1,5-Benzodiazepine-Derivative Labelled with Indium-111 for CCK-2 Receptor Targeting. Molecules, 2021, 26, 918.	1.7	8
60	New insights into the pathogenesis of giant cell arteritis: are they relevant for precision medicine?. Lancet Rheumatology, The, 2021, 3, e874-e885.	2.2	8
61	Cancer Vaccines Co-Targeting HER2/Neu and IGF1R. Cancers, 2019, 11, 517.	1.7	7
62	Immune targeting of autocrine IGF2 hampers rhabdomyosarcoma growth and metastasis. BMC Cancer, 2019, 19, 126.	1.1	7
63	The therapeutic potential of tuftsin-phosphorylcholine in giant cell arteritis. Journal of Autoimmunity, 2019, 98, 113-121.	3.0	7
64	Efficacy of Rituximab Treatment in Vogt-Koyanagi-Harada Disease Poorly Controlled by Traditional Immunosuppressive Treatment. Ocular Immunology and Inflammation, 2021, , 1-6.	1.0	6
65	What Do We Have to Know about PD-L1 Expression in Prostate Cancer? A Systematic Literature Review. Part 5: Epigenetic Regulation of PD-L1. International Journal of Molecular Sciences, 2021, 22, 12314.	1.8	6
66	What Do We Have to Know about PD-L1 Expression in Prostate Cancer? A Systematic Literature Review. Part 7: PD-L1 Expression in Liquid Biopsy. Journal of Personalized Medicine, 2021, 11, 1312.	1.1	6
67	Inhibition of prostate carcinogenesis by combined active immunoprophylaxis. International Journal of Cancer, 2007, 121, 88-94.	2.3	5
68	Inflammatory burden and persistent CT lung abnormalities in COVID-19 patients. Scientific Reports, 2022, 12, 4270.	1.6	5
69	HER-2/neu tolerant and non-tolerant mice for fine assessment of antimetastatic potency of dendritic cell-tumor cell hybrid vaccines. Vaccine, 2011, 29, 4690-4697.	1.7	4
70	Expression of a functional CCR7 chemokine receptor inhibits the post-intravasation steps of metastasis in malignant murine mammary cancer cells. Oncology Reports, 2007, 18, 451-6.	1.2	4
71	Could different aqueous humor and plasma cytokine profiles help differentiate between ocular sarcoidosis and ocular tuberculosis?. Inflammation Research, 2022, 71, 949-961.	1.6	4
72	Survival and Recurrence in Vitreoretinal Lymphoma Simulating Uveitis at Presentation: The Possible Role of Combined Chemotherapy. Ocular Immunology and Inflammation, 2021, , 1-9.	1.0	3

#	Article	IF	Citations
73	Acute-phase reactants during tocilizumab therapy for severe COVID-19 pneumonia. Clinical and Experimental Rheumatology, 2020, 38, 1215-1222.	0.4	3
74	Expression of T cell receptor alpha gene (TCRA) in human rhabdomyosarcoma and other musculo-skeletal sarcomas. Gene, 2005, 353, 16-22.	1.0	2
75	Endothelin-3 production by human rhabdomyosarcoma: A possible new marker with a paracrine role. European Journal of Cancer, 2006, 42, 680-687.	1.3	2
76	AB0563â€Rituximab in patients with takayasu arteritis: a seven patients experience., 2017,,.		2
77	Vogt–Koyanagi–Harada patients show higher frequencies of circulating NKG2Dpos NK and NK T cells. Clinical and Experimental Immunology, 2021, 204, 41-48.	1.1	2
78	Expression of a functional CCR7 chemokine receptor inhibits the post-intravasation steps of metastasis in malignant murine mammary cancer cells. Oncology Reports, 0, , .	1.2	2
79	Predictive factors of clinical outcomes in patients with COVID-19 treated with tocilizumab: A monocentric retrospective analysis. PLoS ONE, 2022, 17, e0262908.	1.1	2
80	Tamoxifen combined to anti-HER-2/neu cell vaccine does not hamper cancer immunopreventive efficacy. Vaccine, 2009, 27, 2065-2069.	1.7	1
81	Large-Vessel Vasculitis. , 2019, , 609-618.		1
82	AB0039â€ROLE OF MESENCHYMAL STEM CELLS ISOLATED FROM DENTAL PULP (DPSCS) IN IMMUNOREGULATION PROCESSES MEDIATED BY PROGRAMMED DEATH-LIGAND 1 (PD-L1). Annals of the Rheumatic Diseases, 2020, 79, 1322.1-1322.	0.5	1
83	EGFR-related miRNAs as potential biomarkers of response to Erlotinib in metastatic NSCLC patients. Annals of Oncology, 2015, 26, vi81.	0.6	0
84	THU0539â€Clinical Presentation of Cryopyrin-Associated Periodic Syndrome (CAPS) in Carriers of the Q703K Mutation in the CIAS1/NLRP3 Gene: Genotype-Phenotype Characterization of a Family. Annals of the Rheumatic Diseases, 2015, 74, 395.2-395.	0.5	0
85	A possible correlation with the response in patients with metastatic lung caner: MicroRNA and Erlotinb. Annals of Oncology, 2016, 27, iv13.	0.6	0
86	SAT0352â€Analysis of Varicella-Zoster Virus in Temporal Artery Biopsies Positive and Negative for Giant Cell Arteritis. Annals of the Rheumatic Diseases, 2016, 75, 794.2-794.	0.5	0
87	SAT0023â€Artery Tertiary Lymphoid Organs Occur in Giant Cell Arteritis. Annals of the Rheumatic Diseases, 2016, 75, 672.1-672.	0.5	0
88	THU0035â€Cytokine profiling of aqueous humor in behÇet's disease patients with active ocular involvement. , 2017, , .		0
89	AB0022â€Cytotoxic profile characterization of nk and nkt cells in patients with behÇet disease. , 2017, , .		0
90	Copper-64 and fluorescein labeled anti-miRNA peptide nucleic acids for the detection of miRNA expression in living cells. Nuclear Medicine and Biology, 2019, 72-73, S44.	0.3	0

#	Article	lF	CITATIONS
91	Abstract 1403: Multiorogan metastasis of human HER-2+ breast cancer in immunodeficient mice. , 2012, , .		O
92	Abstract 2715: Treatment of disseminated HER-2 carcinomas with a HER-2-retargeted oncolytic herpes virus. , 2012, , .		0
93	THU0457 Interleukin-6 expression in inflamed and non-inflamed temporal arteries from patients with giant cell arteritis. , 2018, , .		O
94	THU0314â€RELAPSES AND LONG-TERM REMISSION IN LARGE VESSEL GIANT CELL ARTERITIS IN NORTHERN ITA CHARACTERISTICS AND PREDICTORS IN A LONG-TERM FOLLOW-UP STUDY. Annals of the Rheumatic Diseases, 2020, 79, 386.2-386.	ALY: 0.5	0